论文部分内容阅读
目的:观察谷胱甘肽注射液（阿拓莫兰）对酒精性肝病的疗效。方法:34例酒精性肝病（酒精性脂肪肝、酒精性肝炎、酒精性肝硬化）患者随机分为治疗组34例（阿拓莫兰1.8g/d,静脉滴注,14d为一疗程）,对照组11例（维生素C2.0g,ATP20mg,辅酶A100U,1次/d,静脉滴注,疗程同上）。结果:第一疗程（14d）后症状改善率治疗组为85.0％（29/34）,对照组为40.4％（5/11）;转氨酶恢复至正常者治疗组占73.5％（25/34）,对照组为33.3％（4/11）,P<0.01。第二疗程后症状改善率治疗组为94.0％（32/34）,对照组为53.6％（6/11）,P<0.01;转氨酶恢复至正常者治疗组占88.2％（30/34）,对照组为63.6％（7/11）,（P<0.05）。结论:阿拓莫兰注射液对酒精性肝病患者转氨酶异常有良好治疗作用。
Objective: To observe the effect of glutathione injection (alto moran) on alcoholic liver disease. Methods: Thirty-four patients with alcoholic liver disease (alcoholic fatty liver disease, alcoholic hepatitis and alcoholic cirrhosis) were randomly divided into treatment group (34 cases, treated with ATO Moran 1.8g / d, intravenous drip for 14 days) The control group of 11 patients (vitamin C2.0g, ATP20mg, coenzyme A100U, 1 / d, intravenous infusion, treatment as above). Results: After the first course of treatment (14d), the rate of symptom improvement was 85.0% (29/34) in the treatment group and 40.4% (5/11) in the control group, and 73.5% (25/34) in the treatment group returned to normal. The control group was 33.3% (4/11), P <0.01. After the second course of treatment, the rate of symptom improvement was 94.0% (32/34) in the treatment group and 53.6% (6/11) in the control group (P <0.01); 88.2% (30/34) in the treatment group returned to normal, Group was 63.6% (7/11), (P <0.05). Conclusion: Addon Moran injection on patients with alcoholic liver disease abnormal aminotransferase have a good therapeutic effect.